Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

BACKGROUND: Non-invasive imaging biomarkers underpin the development of molecularly targeted anti-cancer drugs. This study evaluates tumour apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (DW-MRI), as a biomarker of response to the MEK1/2 inhibitor sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Beloueche-Babari, M, Jamin, Y, Arunan, V, Walker-Samuel, S, Revill, M, Smith, P D, Halliday, J, Waterton, J C, Barjat, H, Workman, P, Leach, M O, Robinson, S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776979/
https://www.ncbi.nlm.nih.gov/pubmed/23942066
http://dx.doi.org/10.1038/bjc.2013.456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776979/
https://www.ncbi.nlm.nih.gov/pubmed/23942066
http://dx.doi.org/10.1038/bjc.2013.456

Ejemplares similares